Harigai, Masayoshi <br/><br/>
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.  [electronic resource] 

 -  RMD open  02 2020 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2056-5933 
<br/><br/><label>Standard No.: </label>10.1136/rmdopen-2019-001095  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antirheumatic Agents--adverse effects<br/>Antiviral Agents--therapeutic use<br/>Arthritis, Rheumatoid--complications<br/>Azetidines--administration & dosage<br/>Female<br/>Hepatitis B--chemically induced<br/>Hepatitis B Antibodies--blood<br/>Hepatitis B Surface Antigens--blood<br/>Hepatitis B virus--drug effects<br/>Humans<br/>Immunomodulation<br/>Janus Kinase Inhibitors--administration & dosage<br/>Japan--epidemiology<br/>Latent Infection--chemically induced<br/>Male<br/>Middle Aged<br/>Purines--administration & dosage<br/>Pyrazoles--administration & dosage<br/>Retrospective Studies<br/>Sulfonamides--administration & dosage<br/>Tumor Necrosis Factor Inhibitors--adverse effects<br/>Virus Activation--drug effects